Merck & Co., Inc. is a biopharmaceutical company with a market cap of $214.8 billion, focused on innovative medicines and vaccines. Despite underperforming the market, the stock has declined 18% in the past year. Third-quarter earnings beat expectations, but the stock fell due to lowered revenue forecast. Analysts predict a 17.1% growth in adjusted EPS for 2025. The consensus rating is a “Moderate Buy” with a mean price target of $102.05, offering an 18.7% premium. A Hold rating was maintained with a price target of $95. The highest price target of $137 implies a 59.3% potential upside.

Read more at Barchart: Are Wall Street Analysts Predicting Merck & Co. Stock Will Climb or Sink?